272 related articles for article (PubMed ID: 38367182)
21. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England.
Tan YY; Papez V; Chang WH; Mueller SH; Denaxas S; Lai AG
Lancet Healthy Longev; 2022 Oct; 3(10):e674-e689. PubMed ID: 36150402
[TBL] [Abstract][Full Text] [Related]
22. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
Thompson D
Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
[TBL] [Abstract][Full Text] [Related]
23. Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions.
Roberts MH; Ferguson GT
Pharmacoecon Open; 2021 Mar; 5(1):3-11. PubMed ID: 32557235
[TBL] [Abstract][Full Text] [Related]
24. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019.
Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
J Cancer Policy; 2023 Jun; 36():100424. PubMed ID: 37116794
[TBL] [Abstract][Full Text] [Related]
25. Real-World Data: Applications and Relevance to Cancer Clinical Trials.
Gross AJ; Pisano CE; Khunsriraksakul C; Spratt DE; Park HS; Sun Y; Wang M; Zaorsky NG
Semin Radiat Oncol; 2023 Oct; 33(4):374-385. PubMed ID: 37684067
[TBL] [Abstract][Full Text] [Related]
26. Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies.
Izem R; Buenconsejo J; Davi R; Luan JJ; Tracy L; Gamalo M
Ther Innov Regul Sci; 2022 Sep; 56(5):704-716. PubMed ID: 35676557
[TBL] [Abstract][Full Text] [Related]
27. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.
Vaghela S; Tanni KA; Banerjee G; Sikirica V
Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874
[TBL] [Abstract][Full Text] [Related]
28. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
Lee H; Ahn HS; Kwon S; Kang HY; Han E
Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
[TBL] [Abstract][Full Text] [Related]
29. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
30. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
31. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
32. Ethical pitfalls in neonatal comparative effectiveness trials.
Modi N
Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
[TBL] [Abstract][Full Text] [Related]
33. The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology.
Merola D; Campbell U; Gautam N; Rubens A; Schneeweiss S; Wang SV; Carrigan G; Chia V; Ovbiosa OE; Pinheiro S; Bruno A; Jiao X; Stewart M; Hendricks-Sturrup R; Rodriguez-Watson C; Khosla S; Zhang Y; Rimawi M; Huang J; Taylor A; Becnel L; McRoy L; Eckert J; Taylor B
Clin Pharmacol Ther; 2023 Jun; 113(6):1217-1222. PubMed ID: 36408668
[TBL] [Abstract][Full Text] [Related]
34. Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers.
Magalhães T; Dinis-Oliveira RJ; Taveira-Gomes T
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886214
[TBL] [Abstract][Full Text] [Related]
35. The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making.
Baumfeld Andre E; Carrington N; Siami FS; Hiatt JC; McWilliams C; Hiller C; Surinach A; Zamorano A; Pashos CL; Schulz WL
Clin Pharmacol Ther; 2022 Dec; 112(6):1172-1182. PubMed ID: 35213741
[TBL] [Abstract][Full Text] [Related]
36. Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders.
Facey KM; Rannanheimo P; Batchelor L; Borchardt M; de Cock J
Int J Technol Assess Health Care; 2020 Sep; ():1-10. PubMed ID: 32878663
[TBL] [Abstract][Full Text] [Related]
37. The Medicines Intelligence Centre of Research Excellence: Co-creating real-world evidence to support the evidentiary needs of Australian medicines regulators and payers.
Pratt N; Camacho X; Vajdic C; Degenhardt L; Laba TL; Hillen J; Etherton-Beer C; Preen D; Jorm L; Donnolley N; Havard A; Pearson SA
Int J Popul Data Sci; 2021; 6(3):1726. PubMed ID: 35784493
[TBL] [Abstract][Full Text] [Related]
38. Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments.
Kokkotou E; Anagnostakis M; Evangelou G; Syrigos NK; Gkiozos I
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611092
[TBL] [Abstract][Full Text] [Related]
39. Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups.
Saesen R; Lacombe D; Huys I
ESMO Open; 2023 Apr; 8(2):100878. PubMed ID: 36822113
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
